Abrilumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | ? |
Source | Human |
Target | integrin alpha-4 beta-7 |
Clinical data | |
Other names | AMG 181 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6362H9806N1686O2014S52 |
Molar mass | 143803.34 g·mol−1 |
Abrilumab (INN;[1] development code AMG 181) is a monoclonal antibody designed for the treatment of inflammatory bowel disease, ulcerative colitis, and Crohn's disease.[2]
This drug was developed by MedImmune.
References
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- Experimental monoclonal antibodies
- Drugs developed by AstraZeneca
- All stub articles
- Monoclonal antibody stubs